The Corson Lab research team is developing small molecules as probes and therapeutic leads for the common, blinding afflictions of wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity–all of which are associated with abnormal excess blood vessel growth in the eye (neovascularization).
Specifically, we are working to find novel, small-molecule therapeutic approaches and targets for age-related macular degeneration and other neovascular eye diseases. We are also interested in understanding the biology of, and developing potential therapies for, the pediatric ocular cancer retinoblastoma.
Active Research:
- Novel Antiangiogenic Compounds
- KIF14 as a Novel Oncogene
Keywords:
- chemical biology, angiogenesis, ocular oncology, ophthalmology
Research interests: Drug discovery for eye disease
Tim Corson’s research applies chemical biology approaches to clinical problems in eye disease, notably the neovascularization (abnormal blood vessel growth) seen in diseases like age-related macular degeneration, diabetic retinopathy, and ocular tumors.
Research: Complication of Diabetes and Obesity
Expertise:
- Neurodegenerative Disorders Research
- Ocular Neurobiology Research
The Corson Lab studies: neovascularization; abnormal blood vessel growth in the eye, which is a key feature of diseases like age-related macular degeneration; diabetic retinopathy; retinopathy of prematurity; and cancers of the eye. The lab is interested in finding new pathways that regulate blood vessel growth and targeting these with new chemicals that could be the basis for drugs; and working with collaborators to formulate and test potential therapies.
Keywords: Retina Research
